First clinical trial in younger FH patients announced
The first specific trial to investigate the efficacy and safety of LDL-C lowering therapy in younger (<18 years) people with heterozygous familial hypercholesterolaemia (FH) has been announced.
The double blind HAUSER study (Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic Lipid Disorders) will evaluate treatment with the LDL-C lowering effect of evolocumab over 24 weeks.
The launch of HAUSER follows recent publication of a European Atherosclerosis Society Consensus Paper recommending more active identification of young people with FH and active treatment to lower LDL-C.
